

SmartPA Criteria Proposal

Drug/Drug Class:	Selective Serotonin Reuptake Inhibitor (SSRI) Step Therapy Edit
First Implementation Date:	October 26, 2005
Proposed Date:	September 16, 2021
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate use of selective serotonin reuptake inhibitor (SSRI) agents

Why Issue Selected: MO HealthNet will assess the usage of SSRI agents in the pharmacy program with a primary goal of patient safety. Participants may have multiple prescribers and/or multiple pharmacies caring for them and without a clinical edit it is almost impossible to prevent duplication within a drug class, dangerous drug interactions, or overmedication. By using medical evidence guidelines, this clinical edit can flag potentially dangerous duplicate and high dose therapy for SSRI agents. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

Program-Specific Information:

Date Range FFS 7-1-2020 to 6-30-2021				
Generic Equivalent	Drug Description	Claims	Spend	Avg Spend per Claim
CITALOPRAM HBR	CELEXA 10 MG TAB	15,989	\$254,731.80	\$15.93
	CELEXA 10 MG/5 ML SOL	447	\$27,314.47	\$61.11
	CELEXA 20 MG TAB	36,916	\$586,215.63	\$15.88
	CELEXA 20 MG/10 ML SOL	0	-	-
	CELEXA 40 MG TAB	30,623	\$494,686.95	\$16.15
ESCITALOPRAM OXALATE	LEXAPRO 5 MG TAB	11,324	\$198,226.91	\$17.51
	LEXAPRO 5 MG/5 ML SOL	388	\$52,775.11	\$136.02
	LEXAPRO 10 MG TAB	44,140	\$796,493.09	\$18.04
	LEXAPRO 10 MG/10 ML SOL	0	-	-
	LEXAPRO 20 MG TAB	41,165	\$783,826.06	\$19.04
FLUOXETINE HCL	FLUOXETINE 60 MG TAB	3,291	\$186,770.26	\$56.75
	PROZAC 10 MG CAP	22,416	\$386,038.28	\$17.22
	PROZAC 20 MG CAP	54,352	\$875,930.64	\$16.12
	PROZAC 20 MG/5 ML SOL	2,510	\$175,777.54	\$70.03
	PROZAC 40 MG CAP	37,993	\$678,967.26	\$17.87
	PROZAC WEEKLY 90 MG	300	\$35,789.49	\$119.30
	SARAFEM 10 MG TAB	6,939	\$157,749.29	\$22.73
	SARAFEM 20 MG TAB	7,791	\$234,459.52	\$30.09

SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

FLUVOXAMINE MALEATE	LUVOX 25 MG TAB	514	\$13,477.18	\$26.22
	LUVOX 50 MG TAB	1,660	\$47,450.44	\$28.58
	LUVOX 100 MG TAB	2,510	\$81,815.03	\$32.60
	LUVOX CR 100 MG CAP	164	\$39,245.90	\$239.30
	LUVOX CR 150 MG CAP	306	\$78,357.73	\$256.07
PAROXETINE HCL	PAXIL 10 MG TAB	5,175	\$93,933.22	\$18.15
	PAXIL 10 MG/5 ML SUSP	51	\$21,184.83	\$415.39
	PAXIL 20 MG TAB	10,350	\$177,863.42	\$17.18
	PAXIL 30 MG TAB	4,341	\$82,973.57	\$19.11
	PAXIL 40 MG TAB	8,254	\$160,674.21	\$19.47
	PAXIL CR 12.5 MG TAB	103	\$4,931.47	\$47.88
	PAXIL CR 25 MG TAB	353	\$22,410.98	\$63.49
	PAXIL CR 37.5 MG TAB	203	\$12,402.76	\$61.10
PAROXETINE MESYLATE	BRISDELLE 7.5 MG CAP	52	\$7,206.00	\$138.58
	PEXEVA 10 MG TAB	0	-	-
	PEXEVA 20 MG TAB	0	-	-
	PEXEVA 30 MG TAB	8	\$3,451.00	\$431.38
	PEXEVA 40 MG TAB	13	\$5,806.98	\$446.69
SERTRALINE HCL	ZOLOFT 20 MG/ML CONC	1,092	\$66,342.11	\$60.75
	ZOLOFT 25 MG TAB	32,903	\$577,833.61	\$17.56
	ZOLOFT 50 MG TAB	73,485	\$1,306,916.34	\$17.78
	ZOLOFT 100 MG TAB	77,971	\$1,445,619.45	\$18.54
VILAZODONE HCL	VIIBRYD 10 MG-20 MG PK	57	\$16,659.45	\$292.27
	VIIBRYD 10 MG TAB	709	\$202,643.94	\$285.82
	VIIBRYD 20 MG TAB	2,315	\$669,920.27	\$289.38
	VIIBRYD 40 MG TAB	3,967	\$1,122,919.60	\$283.07
VORTIOXETINE HBR	TRINTELLIX 5 MG TAB	1,541	\$602,555.65	\$391.02
	TRINTELLIX 10 MG TAB	5,091	\$2,015,014.86	\$395.80
	TRINTELLIX 20 MG TAB	7,203	\$2,786,867.54	\$386.90
Total		556,975	\$17,592,229.84	\$31.59

Type of Criteria: Increased risk of ADE
 Appropriate Indications

Preferred Drug List
 Clinical Edit

Data Sources: Only Administrative Databases

Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Selective serotonin reuptake inhibitor (SSRI) agents
- Age range: All appropriate MO HealthNet participants aged 5 years and older

Approval Criteria

- Participant aged 5 years or older **AND**
- Documented compliance to current SSRI therapy regimen (90 days in the past 120 days) **OR**
- Documented adequate initial therapeutic intervention with 1 or more reference products (see Appendix A) **OR**
- Documented ADE/ADR to reference products
- Documented appropriate diagnosis required for:
 - Participants < 18 years of age **OR**
 - Participants < 26 years of age who are also enrolled in foster care

SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Claim exceeds maximum dosage limits (see Appendix B)
- Participants < 18 years of age: history of > 2 SSRI agents for more than 30 days in the past 90 days
- Participants ≥ 18 years of age: history of > 2 SSRI agents for more than 60 days in the past 90 days
- Participant is on more than one SSRI agent and one SNRI agent concurrently for more than 30 days

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception code "0681" (Step Therapy)
Rule Type: CE

Appendix A – SSRI reference products

- CITALOPRAM SOLN/TAB
- ESCITALOPRAM SOLN/TAB
- FLUOXETINE CAP/SOLN
- FLUOXETINE TAB 10 MG AND 20 MG
- FLUVOXAMINE TAB
- PAROXETINE TAB
- SERTRALINE SOLN/TAB

Appendix B – Maximum Daily Dosage Limits

Generic Equivalent	Max Daily Dose
CITALOPRAM	60mg
ESCITALOPRAM	20mg
FLUOXETINE	80mg
FLUVOXAMINE	300mg
PAROXETINE	80mg
SERTRALINE	200mg
VILAZODONE	40mg
VORTIOXETINE	20mg

References

- Facts & Comparisons. Selective Serotonin Reuptake Inhibitors. Accessed August 9, 2021.

SmartPA Clinical Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.